

Special Issue

Epigenetics and Metabolic Disorders

Message from the Guest Editor

Metabolic diseases represent a wide spectrum of disorders arising from disruptions in the body's metabolic processes. The constantly increasing incidence and prevalence of metabolic disorders make them not only an epidemiological issue but also an economic and societal problem. One cause of metabolic diseases is epigenetic changes in the regulation of genes that control metabolic processes. Understanding epigenetic changes in the context of the development of metabolic diseases has the potential to influence processes related to the onset and progression of these diseases and may lead to new strategies in prevention and treatment. This Special Issue welcomes original research and review articles dedicated to epigenetic processes underlying the onset and development of metabolic diseases. We encourage authors to contribute works related to (but not limited to):

- Prenatal epigenetic changes related to metabolic diseases
- Heredity and epigenetic changes underlying metabolic diseases
- The role of epigenetics in relationship of environmental factors and metabolic diseases
- Therapeutic interventions targeting abnormal epigenetic markers associated with metabolic diseases

Guest Editor

Dr. Patrik Krumpolec

Medirex Group Academy, 949 05 Nitra, Slovakia

Deadline for manuscript submissions

30 September 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/216063

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).